The FDA asked for 75 years to produce data about Pfizer and BioNTech vaccine, 20 years more than the previous request.
The agency at the court said that they could work faster than the previously proposed 500-pages a month rate.
Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender
However, they said that there are more than 59,000 pages more than previously said.
According to their scheduled timeline, they would share the entire data in 2096.
“If you find what you are reading difficult to believe—that is because it is dystopian for the government to give Pfizer billions, mandate Americans to take its product, prohibit Americans from suing for harms, but yet refuse to let Americans see the data underlying its licensure,” Siri said.
This case was brought on behalf of the Public Health and Medical Professionals for Transparency. In the group are Dr. Carole Browner, professor at the University of California; Peter Doshi, a professor at the University of Maryland’s School of Pharmacy and Dr. Harvey Risch, a professor of epidemiology at the Yale School of Public Health.
The group said that the information has to be shared as soon as possible because the FDA spent 108 days reviewing it before giving the emergency use authorization to Pfizer.
This is crucial because Americans are mandated to take the shots forcefully. Otherwise, they will face termination.
“The entire purpose of FOIA is government transparency. In multiple recent cases, in upholding the FOIA’s requirement to ‘make the records promptly available,’ courts have required agencies, including the FDA, to produce 10,000 or more pages per month, and those cases did not involve a request nearly this important–i.e., the data underlying licensure of a liability-free product that the federal government requires nearly all Americans to receive,” Siri said.
“As the present pandemic rages on, independent review of these documents by outside scientists is urgently needed to assist with addressing the shortcomings and issues with the response to the pandemic to date.”
The FDA shared that the Center for Biologics Evaluation and research keeps the records by the plaintiff, and it has ten members, where two are new. That’s the reason why they are slower in processing the pages.
A faster rate than requested would divert “significant resources away from the processing of other FOIA requests that are also in litigation.’’
“In sum, FDA’s proposed processing schedule is fair to the plaintiff.”